Provided by Tiger Trade Technology Pte. Ltd.

Anaptysbio Inc

48.63
-1.6300-3.24%
Post-market: 48.630.00000.00%19:30 EDT
Volume:512.33K
Turnover:24.93M
Market Cap:1.45B
PE:6.95
High:50.98
Open:49.94
Low:48.13
Close:50.26
52wk High:73.30
52wk Low:29.48
Shares:29.90M
Float Shares:21.33M
Volume Ratio:0.76
T/O Rate:2.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.00
EPS(LYR):3.50
ROE:-114.55%
ROA:6.78%
PB:137.35
PE(LYR):13.90

Loading ...

Piper Sandler Releases a Buy Rating on AnaptysBio (ANAB)

TIPRANKS
·
May 04

Assessing AnaptysBio’s Valuation After Strong Recent Share Price Momentum

Simply Wall St.
·
May 03

U.S. Earnings Preview: After Market Close May 1

Dow Jones
·
May 02

AnaptysBio Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Apr 28

AnaptysBio Inc : Leerink Partners Raises Target Price to $85.00 From $66.00

THOMSON REUTERS
·
Apr 28

AnaptysBio Shares Rise After Delaware Court Dismisses Tesaro Claim

Dow Jones
·
Apr 28

BRIEF-GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged

Reuters
·
Apr 27

GSK: GSK and Tesaro Firmly of View That Allegations Are Entirely Without Merit and Remain Focused on Pursuing That Claim at Trial

THOMSON REUTERS
·
Apr 27

AnaptysBio files amended 8-K with pro forma financials for First Tracks spin-off

Reuters
·
Apr 25

AnaptysBio Inc - Court Ruling Preserves Current Royalty Rates and Rejects Tesaro's Royalty Reduction Request

THOMSON REUTERS
·
Apr 25

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

THOMSON REUTERS
·
Apr 25

Delaware Chancery Court dismisses Tesaro anticipatory breach claim against AnaptysBio

Reuters
·
Apr 25

Assessing AnaptysBio (ANAB) Valuation As It Shifts To A Royalty Focus After Spinning Off Operations

Simply Wall St.
·
Apr 24

First Tracks Biotherapeutics initial beneficial ownership filing shows EcoR1 Capital stake

Reuters
·
Apr 23

AnaptysBio price target lowered to $60 from $90 at UBS

TIPRANKS
·
Apr 22

UBS Adjusts Price Target on AnaptysBio to $60 From $90, Maintains Buy Rating

MT Newswires Live
·
Apr 22

AnaptysBio Is Maintained at Buy by UBS

Dow Jones
·
Apr 22

AnaptysBio price target lowered to $60 from $90 at UBS

TIPRANKS
·
Apr 21

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Apr 21

AnaptysBio Completes Spinoff of First Tracks Biotherapeutics; Shares Surge

MT Newswires Live
·
Apr 20